Over the last 12 months, Aldeyra Therapeutics insiders reported 1 buy totaling $418K and no sales across SEC Form 4 filings.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Brady Todd CPresident and CEO · O·D | ▲ Buy | 250,000 | $1.67 | $418K | +17% | — |
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALDX feed.